Skip to main content
Clinical Trials/NCT00209404
NCT00209404CompletedPhase 4

Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA)

GE Healthcare1 site in 1 country50 target enrollmentStarted: July 1, 2005Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
50
Locations
1
Primary Endpoint
Change in mean heart rate

Study Overview

Brief Summary

Image quality in coronary artery computed tomography is influenced by the heart rate variation during the examination. The purpose of this clinical trial is to investigate the change in heart rate following injection of a contrast medium called Visipaque™ (iodixanol). Image quality and diagnostic quality of the examination will be evaluated.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Subjects with low to moderate suspicion of coronary artery disease referred for retrospective electrocardiogram (ECG)-gated multidetector row computed tomography coronary angiography and with a heart rate >75 beats per minute (bpm) will be included.

Exclusion Criteria

  • •Subjects who take medications that slow down the heart rate or present cardiac arrhythmia at rest will not be included.

Outcomes

Primary Outcomes

Change in mean heart rate

Secondary Outcomes

  • Image quality
  • Diagnostic quality
  • Overall diagnostic information
  • Frequency and intensity of adverse events

Investigators

Sponsor Class
Industry

Study Sites (1)

Loading locations...

Similar Trials